#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=2. Mutations Induced along with Genomic Destabilization
1-1	0-2	2.	_	_	_	_
1-2	3-12	Mutations	abstract[1]	new[1]	coref	8-1[60_1]
1-3	13-20	Induced	abstract[1]	new[1]	_	_
1-4	21-26	along	abstract[1]	new[1]	_	_
1-5	27-31	with	abstract[1]	new[1]	_	_
1-6	32-39	Genomic	abstract[1]|abstract[2]	new[1]|new[2]	coref	11-14[94_2]
1-7	40-55	Destabilization	abstract[1]|abstract[2]	new[1]|new[2]	_	_

#Text=2.1. Mutation Rate and Its Association with Cancer Risk
2-1	56-60	2.1.	_	_	_	_
2-2	61-69	Mutation	abstract|abstract[4]|abstract[5]	new|new[4]|new[5]	ana|ana|coref	2-5[0_4]|4-10[0_5]|5-3
2-3	70-74	Rate	abstract[4]|abstract[5]	new[4]|new[5]	_	_
2-4	75-78	and	abstract[5]	new[5]	_	_
2-5	79-82	Its	abstract[5]|abstract|organization[7]	new[5]|giv|new[7]	coref	6-20[36_0]
2-6	83-94	Association	abstract[5]|organization[7]	new[5]|new[7]	_	_
2-7	95-99	with	abstract[5]|organization[7]	new[5]|new[7]	_	_
2-8	100-106	Cancer	abstract[5]|organization[7]|abstract|abstract[9]	new[5]|new[7]|new|new[9]	coref|coref	6-15|6-27[38_9]
2-9	107-111	Risk	abstract[5]|organization[7]|abstract[9]	new[5]|new[7]|new[9]	_	_

#Text=In normal human cells , DNA is usually replicated by high-fidelity polymerases δ and ε .
3-1	112-114	In	_	_	_	_
3-2	115-121	normal	animal[10]	new[10]	coref	7-45[56_10]
3-3	122-127	human	animal[10]	new[10]	_	_
3-4	128-133	cells	animal[10]	new[10]	_	_
3-5	134-135	,	_	_	_	_
3-6	136-139	DNA	abstract	new	coref	25-19
3-7	140-142	is	_	_	_	_
3-8	143-150	usually	_	_	_	_
3-9	151-161	replicated	_	_	_	_
3-10	162-164	by	_	_	_	_
3-11	165-178	high-fidelity	substance[12]|abstract[13]	new[12]|new[13]	coref	4-4[16_12]
3-12	179-190	polymerases	substance[12]|abstract[13]	new[12]|new[13]	_	_
3-13	191-192	δ	abstract[13]	new[13]	_	_
3-14	193-196	and	_	_	_	_
3-15	197-198	ε	abstract	new	coref	6-9
3-16	199-200	.	_	_	_	_

#Text=Errors caused by those polymerases are primarily repaired by their proofreading system ( Table 1 ) , and the remaining errors are targeted by the mismatch repair ( MMR ) system .
4-1	201-207	Errors	abstract[15]	new[15]	coref	4-19[20_15]
4-2	208-214	caused	abstract[15]	new[15]	_	_
4-3	215-217	by	abstract[15]	new[15]	_	_
4-4	218-223	those	abstract[15]|substance[16]	new[15]|giv[16]	coref	23-22[141_16]
4-5	224-235	polymerases	abstract[15]|substance[16]	new[15]|giv[16]	_	_
4-6	236-239	are	_	_	_	_
4-7	240-249	primarily	_	_	_	_
4-8	250-258	repaired	_	_	_	_
4-9	259-261	by	_	_	_	_
4-10	262-267	their	abstract|abstract[19]	giv|new[19]	coref|coref	4-25[24_19]|7-6[42_0]
4-11	268-280	proofreading	abstract|abstract[19]	new|new[19]	coref	6-5
4-12	281-287	system	abstract[19]	new[19]	_	_
4-13	288-289	(	_	_	_	_
4-14	290-295	Table	_	_	_	_
4-15	296-297	1	_	_	_	_
4-16	298-299	)	_	_	_	_
4-17	300-301	,	_	_	_	_
4-18	302-305	and	_	_	_	_
4-19	306-309	the	abstract[20]	giv[20]	coref	15-20[107_20]
4-20	310-319	remaining	abstract[20]	giv[20]	_	_
4-21	320-326	errors	abstract[20]	giv[20]	_	_
4-22	327-330	are	_	_	_	_
4-23	331-339	targeted	_	_	_	_
4-24	340-342	by	_	_	_	_
4-25	343-346	the	abstract[24]	giv[24]	_	_
4-26	347-355	mismatch	object|abstract[22]|abstract[24]	new|new[22]|giv[24]	appos	4-29[0_22]
4-27	356-362	repair	abstract[22]|abstract[24]	new[22]|giv[24]	_	_
4-28	363-364	(	abstract[24]	giv[24]	_	_
4-29	365-368	MMR	abstract|abstract[24]	giv|giv[24]	coref	6-3
4-30	369-370	)	abstract[24]	giv[24]	_	_
4-31	371-377	system	abstract[24]	giv[24]	_	_
4-32	378-379	.	_	_	_	_

#Text=Consequently , mutation is largely suppressed during normal replication .
5-1	380-392	Consequently	_	_	_	_
5-2	393-394	,	_	_	_	_
5-3	395-403	mutation	abstract	giv	coref	6-21
5-4	404-406	is	_	_	_	_
5-5	407-414	largely	_	_	_	_
5-6	415-425	suppressed	_	_	_	_
5-7	426-432	during	_	_	_	_
5-8	433-439	normal	event[26]	new[26]	coref	10-26[0_26]
5-9	440-451	replication	event[26]	new[26]	_	_
5-10	452-453	.	_	_	_	_

#Text=Deficiencies in MMR and proofreading performed by polymerase ε are associated with hypermutation and cancer predisposition ; thus , the mutation rate is strongly associated with cancer risk .
6-1	454-466	Deficiencies	abstract[27]	new[27]	_	_
6-2	467-469	in	abstract[27]	new[27]	_	_
6-3	470-473	MMR	abstract[27]|abstract	new[27]|giv	coref	23-19
6-4	474-477	and	abstract[27]	new[27]	_	_
6-5	478-490	proofreading	abstract[27]|abstract	new[27]|giv	_	_
6-6	491-500	performed	abstract[27]	new[27]	_	_
6-7	501-503	by	abstract[27]	new[27]	_	_
6-8	504-514	polymerase	abstract[27]|substance	new[27]|new	_	_
6-9	515-516	ε	abstract[27]|abstract	new[27]|giv	coref	24-27
6-10	517-520	are	_	_	_	_
6-11	521-531	associated	_	_	_	_
6-12	532-536	with	_	_	_	_
6-13	537-550	hypermutation	abstract	new	coref	11-10
6-14	551-554	and	_	_	_	_
6-15	555-561	cancer	abstract|abstract[34]	giv|new[34]	coref	6-27
6-16	562-576	predisposition	abstract[34]	new[34]	_	_
6-17	577-578	;	_	_	_	_
6-18	579-583	thus	_	_	_	_
6-19	584-585	,	_	_	_	_
6-20	586-589	the	abstract[36]	giv[36]	coref	7-6[41_36]
6-21	590-598	mutation	abstract|abstract[36]	giv|giv[36]	coref	7-6
6-22	599-603	rate	abstract[36]	giv[36]	_	_
6-23	604-606	is	_	_	_	_
6-24	607-615	strongly	_	_	_	_
6-25	616-626	associated	_	_	_	_
6-26	627-631	with	_	_	_	_
6-27	632-638	cancer	abstract|abstract[38]	giv|giv[38]	coref|coref	7-9|7-9[44_38]
6-28	639-643	risk	abstract[38]	giv[38]	_	_
6-29	644-645	.	_	_	_	_

#Text=However , this association between mutation rate and cancer risk may be unrelated to cell division frequency and resultant changes in cell number , as aptly pointed out by Peto ’s paradox : cancer incidence does not appear to correlate with the number of cells in an organism at the species level .
7-1	646-653	However	_	_	_	_
7-2	654-655	,	_	_	_	_
7-3	656-660	this	abstract[39]	new[39]	coref	15-30[109_39]
7-4	661-672	association	abstract[39]	new[39]	_	_
7-5	673-680	between	abstract[39]	new[39]	_	_
7-6	681-689	mutation	abstract[39]|abstract|abstract[41]|abstract[42]	new[39]|giv|giv[41]|giv[42]	coref	9-12
7-7	690-694	rate	abstract[39]|abstract[41]|abstract[42]	new[39]|giv[41]|giv[42]	_	_
7-8	695-698	and	abstract[39]|abstract[42]	new[39]|giv[42]	_	_
7-9	699-705	cancer	abstract[39]|abstract[42]|abstract|abstract[44]	new[39]|giv[42]|giv|giv[44]	coref	7-34
7-10	706-710	risk	abstract[39]|abstract[42]|abstract[44]	new[39]|giv[42]|giv[44]	_	_
7-11	711-714	may	_	_	_	_
7-12	715-717	be	_	_	_	_
7-13	718-727	unrelated	_	_	_	_
7-14	728-730	to	_	_	_	_
7-15	731-735	cell	object|abstract[46]|abstract[47]	new|new[46]|new[47]	coref|coref	7-22|27-9[169_46]
7-16	736-744	division	abstract[46]|abstract[47]	new[46]|new[47]	_	_
7-17	745-754	frequency	abstract[47]	new[47]	_	_
7-18	755-758	and	_	_	_	_
7-19	759-768	resultant	abstract[48]	new[48]	_	_
7-20	769-776	changes	abstract[48]	new[48]	_	_
7-21	777-779	in	abstract[48]	new[48]	_	_
7-22	780-784	cell	abstract[48]|object|abstract[50]	new[48]|giv|new[50]	coref|coref	7-42[55_50]|27-10
7-23	785-791	number	abstract[48]|abstract[50]	new[48]|new[50]	_	_
7-24	792-793	,	_	_	_	_
7-25	794-796	as	_	_	_	_
7-26	797-802	aptly	_	_	_	_
7-27	803-810	pointed	_	_	_	_
7-28	811-814	out	_	_	_	_
7-29	815-817	by	_	_	_	_
7-30	818-822	Peto	person[51]|abstract[52]	new[51]|new[52]	_	_
7-31	823-825	’s	person[51]|abstract[52]	new[51]|new[52]	_	_
7-32	826-833	paradox	abstract[52]	new[52]	_	_
7-33	834-835	:	_	_	_	_
7-34	836-842	cancer	abstract|abstract[54]	giv|new[54]	coref	8-3
7-35	843-852	incidence	abstract[54]	new[54]	_	_
7-36	853-857	does	_	_	_	_
7-37	858-861	not	_	_	_	_
7-38	862-868	appear	_	_	_	_
7-39	869-871	to	_	_	_	_
7-40	872-881	correlate	_	_	_	_
7-41	882-886	with	_	_	_	_
7-42	887-890	the	abstract[55]	giv[55]	_	_
7-43	891-897	number	abstract[55]	giv[55]	_	_
7-44	898-900	of	abstract[55]	giv[55]	_	_
7-45	901-906	cells	abstract[55]|animal[56]	giv[55]|giv[56]	coref	8-3[62_56]
7-46	907-909	in	abstract[55]|animal[56]	giv[55]|giv[56]	_	_
7-47	910-912	an	abstract[55]|animal[56]|animal[57]	giv[55]|giv[56]|new[57]	_	_
7-48	913-921	organism	abstract[55]|animal[56]|animal[57]	giv[55]|giv[56]|new[57]	_	_
7-49	922-924	at	_	_	_	_
7-50	925-928	the	abstract[59]	new[59]	_	_
7-51	929-936	species	abstract|abstract[59]	new|new[59]	_	_
7-52	937-942	level	abstract[59]	new[59]	_	_
7-53	943-944	.	_	_	_	_

#Text=Mutations in cancer cells are not induced randomly .
8-1	945-954	Mutations	abstract[60]	giv[60]	coref	14-2[100_60]
8-2	955-957	in	abstract[60]	giv[60]	_	_
8-3	958-964	cancer	abstract[60]|abstract|animal[62]	giv[60]|giv|giv[62]	coref|coref	14-7|14-7[102_62]
8-4	965-970	cells	abstract[60]|animal[62]	giv[60]|giv[62]	_	_
8-5	971-974	are	_	_	_	_
8-6	975-978	not	_	_	_	_
8-7	979-986	induced	_	_	_	_
8-8	987-995	randomly	_	_	_	_
8-9	996-997	.	_	_	_	_

#Text=Based on whole-genome and exome analyses , chromatin loci with higher mutation levels can be characterized as ( I ) gene loci that are not highly expressed , ( II ) chromosome regions replicating in late S phase , ( III ) heterochromatic loci , and ( IV ) loci with closed chromatin that is not sensitive to DNase I. Mutation rates differ by severalfold between high- and low-mutation loci .
9-1	998-1003	Based	abstract[66]	new[66]	_	_
9-2	1004-1006	on	abstract[66]	new[66]	_	_
9-3	1007-1019	whole-genome	abstract[64]|abstract[66]	new[64]|new[66]	_	_
9-4	1020-1023	and	abstract[64]|abstract[66]	new[64]|new[66]	_	_
9-5	1024-1029	exome	abstract|abstract[64]|abstract[66]	new|new[64]|new[66]	_	_
9-6	1030-1038	analyses	abstract[64]|abstract[66]	new[64]|new[66]	_	_
9-7	1039-1040	,	abstract[66]	new[66]	_	_
9-8	1041-1050	chromatin	substance|abstract[66]	new|new[66]	coref	9-52[77_0]
9-9	1051-1055	loci	abstract[66]	new[66]	_	_
9-10	1056-1060	with	abstract[66]	new[66]	_	_
9-11	1061-1067	higher	abstract[66]|abstract[68]	new[66]|new[68]	_	_
9-12	1068-1076	mutation	abstract[66]|abstract|abstract[68]	new[66]|giv|new[68]	coref	9-61
9-13	1077-1083	levels	abstract[66]|abstract[68]	new[66]|new[68]	_	_
9-14	1084-1087	can	_	_	_	_
9-15	1088-1090	be	_	_	_	_
9-16	1091-1104	characterized	_	_	_	_
9-17	1105-1107	as	_	_	_	_
9-18	1108-1109	(	_	_	_	_
9-19	1110-1111	I	_	_	_	_
9-20	1112-1113	)	_	_	_	_
9-21	1114-1118	gene	abstract|abstract[70]	new|new[70]	_	_
9-22	1119-1123	loci	abstract[70]	new[70]	_	_
9-23	1124-1128	that	abstract[70]	new[70]	_	_
9-24	1129-1132	are	abstract[70]	new[70]	_	_
9-25	1133-1136	not	abstract[70]	new[70]	_	_
9-26	1137-1143	highly	abstract[70]	new[70]	_	_
9-27	1144-1153	expressed	abstract[70]	new[70]	_	_
9-28	1154-1155	,	_	_	_	_
9-29	1156-1157	(	_	_	_	_
9-30	1158-1160	II	_	_	_	_
9-31	1161-1162	)	_	_	_	_
9-32	1163-1173	chromosome	place|place[72]	new|new[72]	_	_
9-33	1174-1181	regions	place[72]	new[72]	_	_
9-34	1182-1193	replicating	place[72]	new[72]	_	_
9-35	1194-1196	in	place[72]	new[72]	_	_
9-36	1197-1201	late	place[72]|abstract[74]	new[72]|new[74]	_	_
9-37	1202-1203	S	place[72]|person|abstract[74]	new[72]|new|new[74]	_	_
9-38	1204-1209	phase	place[72]|abstract[74]	new[72]|new[74]	_	_
9-39	1210-1211	,	_	_	_	_
9-40	1212-1213	(	_	_	_	_
9-41	1214-1217	III	_	_	_	_
9-42	1218-1219	)	_	_	_	_
9-43	1220-1235	heterochromatic	abstract[75]	new[75]	coref	9-67[82_75]
9-44	1236-1240	loci	abstract[75]	new[75]	_	_
9-45	1241-1242	,	_	_	_	_
9-46	1243-1246	and	_	_	_	_
9-47	1247-1248	(	_	_	_	_
9-48	1249-1251	IV	_	_	_	_
9-49	1252-1253	)	_	_	_	_
9-50	1254-1258	loci	event[76]	new[76]	_	_
9-51	1259-1263	with	event[76]	new[76]	_	_
9-52	1264-1270	closed	event[76]|substance[77]	new[76]|giv[77]	_	_
9-53	1271-1280	chromatin	event[76]|substance[77]	new[76]|giv[77]	_	_
9-54	1281-1285	that	event[76]|substance[77]	new[76]|giv[77]	_	_
9-55	1286-1288	is	event[76]|substance[77]	new[76]|giv[77]	_	_
9-56	1289-1292	not	event[76]|substance[77]	new[76]|giv[77]	_	_
9-57	1293-1302	sensitive	event[76]|substance[77]	new[76]|giv[77]	_	_
9-58	1303-1305	to	event[76]|substance[77]	new[76]|giv[77]	_	_
9-59	1306-1311	DNase	event[76]|substance[77]|abstract	new[76]|giv[77]|new	_	_
9-60	1312-1314	I.	event[76]|abstract	new[76]|new	_	_
9-61	1315-1323	Mutation	event[76]|abstract|abstract[81]	new[76]|giv|new[81]	coref|coref	13-1|26-3[159_81]
9-62	1324-1329	rates	event[76]|abstract[81]	new[76]|new[81]	_	_
9-63	1330-1336	differ	event[76]	new[76]	_	_
9-64	1337-1339	by	event[76]	new[76]	_	_
9-65	1340-1351	severalfold	event[76]	new[76]	_	_
9-66	1352-1359	between	event[76]	new[76]	_	_
9-67	1360-1365	high-	event[76]|abstract[82]	new[76]|giv[82]	coref	10-20[87_82]
9-68	1366-1369	and	event[76]|abstract[82]	new[76]|giv[82]	_	_
9-69	1370-1382	low-mutation	event[76]|abstract[82]	new[76]|giv[82]	_	_
9-70	1383-1387	loci	event[76]|abstract[82]	new[76]|giv[82]	_	_
9-71	1388-1389	.	_	_	_	_

#Text=Although the source of these differences remains unclear , the phenomenon might be associated with genomic instability , as heterochromatic loci are often subjected to replication stress and chromosomal rearrangements .
10-1	1390-1398	Although	_	_	_	_
10-2	1399-1402	the	abstract[83]	new[83]	_	_
10-3	1403-1409	source	abstract[83]	new[83]	_	_
10-4	1410-1412	of	abstract[83]	new[83]	_	_
10-5	1413-1418	these	abstract[83]|abstract[84]	new[83]|new[84]	_	_
10-6	1419-1430	differences	abstract[83]|abstract[84]	new[83]|new[84]	_	_
10-7	1431-1438	remains	_	_	_	_
10-8	1439-1446	unclear	_	_	_	_
10-9	1447-1448	,	_	_	_	_
10-10	1449-1452	the	abstract[85]	new[85]	_	_
10-11	1453-1463	phenomenon	abstract[85]	new[85]	_	_
10-12	1464-1469	might	_	_	_	_
10-13	1470-1472	be	_	_	_	_
10-14	1473-1483	associated	_	_	_	_
10-15	1484-1488	with	_	_	_	_
10-16	1489-1496	genomic	abstract[86]	new[86]	coref	28-7[175_86]
10-17	1497-1508	instability	abstract[86]	new[86]	_	_
10-18	1509-1510	,	_	_	_	_
10-19	1511-1513	as	_	_	_	_
10-20	1514-1529	heterochromatic	abstract[87]	giv[87]	_	_
10-21	1530-1534	loci	abstract[87]	giv[87]	_	_
10-22	1535-1538	are	_	_	_	_
10-23	1539-1544	often	_	_	_	_
10-24	1545-1554	subjected	_	_	_	_
10-25	1555-1557	to	_	_	_	_
10-26	1558-1569	replication	event|abstract[89]	giv|new[89]	ana|coref	11-3[0_89]|15-23[108_0]
10-27	1570-1576	stress	abstract[89]	new[89]	_	_
10-28	1577-1580	and	_	_	_	_
10-29	1581-1592	chromosomal	event[90]	new[90]	_	_
10-30	1593-1607	rearrangements	event[90]	new[90]	_	_
10-31	1608-1609	.	_	_	_	_

#Text=Consistent with this , a recent study reported that hypermutation is associated with genomic destabilization .
11-1	1610-1620	Consistent	_	_	_	_
11-2	1621-1625	with	_	_	_	_
11-3	1626-1630	this	abstract	giv	_	_
11-4	1631-1632	,	_	_	_	_
11-5	1633-1634	a	abstract[92]	new[92]	coref	15-3[104_92]
11-6	1635-1641	recent	abstract[92]	new[92]	_	_
11-7	1642-1647	study	abstract[92]	new[92]	_	_
11-8	1648-1656	reported	_	_	_	_
11-9	1657-1661	that	_	_	_	_
11-10	1662-1675	hypermutation	abstract	giv	coref	17-8
11-11	1676-1678	is	_	_	_	_
11-12	1679-1689	associated	_	_	_	_
11-13	1690-1694	with	_	_	_	_
11-14	1695-1702	genomic	abstract[94]	giv[94]	coref	15-39[113_94]
11-15	1703-1718	destabilization	abstract[94]	giv[94]	_	_
11-16	1719-1720	.	_	_	_	_

#Text=2.2.
12-1	1721-1725	2.2.	abstract	new	_	_

#Text=Mutation Induction when Replication-Stress-Associated DSBs Accumulate
13-1	1726-1734	Mutation	abstract|abstract[97]	giv|new[97]	coref	26-5
13-2	1735-1744	Induction	abstract[97]	new[97]	_	_
13-3	1745-1749	when	abstract[97]	new[97]	_	_
13-4	1750-1779	Replication-Stress-Associated	abstract[97]|abstract|abstract[99]	new[97]|new|new[99]	coref|coref	15-32|15-32[111_99]
13-5	1780-1784	DSBs	abstract[97]|abstract[99]	new[97]|new[99]	_	_
13-6	1785-1795	Accumulate	abstract[97]	new[97]	_	_

#Text=Among the many mutations induced in cancer cells , somatically-induced replicative mutations are the most prominent .
14-1	1796-1801	Among	_	_	_	_
14-2	1802-1805	the	abstract[100]	giv[100]	coref	14-10[103_100]
14-3	1806-1810	many	abstract[100]	giv[100]	_	_
14-4	1811-1820	mutations	abstract[100]	giv[100]	_	_
14-5	1821-1828	induced	abstract[100]	giv[100]	_	_
14-6	1829-1831	in	abstract[100]	giv[100]	_	_
14-7	1832-1838	cancer	abstract[100]|abstract|animal[102]	giv[100]|giv|giv[102]	coref|coref	16-9[115_102]|28-20
14-8	1839-1844	cells	abstract[100]|animal[102]	giv[100]|giv[102]	_	_
14-9	1845-1846	,	_	_	_	_
14-10	1847-1866	somatically-induced	abstract[103]	giv[103]	coref	15-7[105_103]
14-11	1867-1878	replicative	abstract[103]	giv[103]	_	_
14-12	1879-1888	mutations	abstract[103]	giv[103]	_	_
14-13	1889-1892	are	_	_	_	_
14-14	1893-1896	the	_	_	_	_
14-15	1897-1901	most	_	_	_	_
14-16	1902-1911	prominent	_	_	_	_
14-17	1912-1913	.	_	_	_	_

#Text=Based on a recent study , such replicative mutations can be separated into two types : those induced as random errors during canonical replication , and those induced in association with replication-stress-associated DSBs that accumulate in association with genomic destabilization .
15-1	1914-1919	Based	_	_	_	_
15-2	1920-1922	on	_	_	_	_
15-3	1923-1924	a	abstract[104]	giv[104]	_	_
15-4	1925-1931	recent	abstract[104]	giv[104]	_	_
15-5	1932-1937	study	abstract[104]	giv[104]	_	_
15-6	1938-1939	,	_	_	_	_
15-7	1940-1944	such	abstract[105]	giv[105]	coref	20-3[126_105]
15-8	1945-1956	replicative	abstract[105]	giv[105]	_	_
15-9	1957-1966	mutations	abstract[105]	giv[105]	_	_
15-10	1967-1970	can	_	_	_	_
15-11	1971-1973	be	_	_	_	_
15-12	1974-1983	separated	_	_	_	_
15-13	1984-1988	into	_	_	_	_
15-14	1989-1992	two	abstract[106]	new[106]	_	_
15-15	1993-1998	types	abstract[106]	new[106]	_	_
15-16	1999-2000	:	_	_	_	_
15-17	2001-2006	those	_	_	_	_
15-18	2007-2014	induced	_	_	_	_
15-19	2015-2017	as	_	_	_	_
15-20	2018-2024	random	abstract[107]	giv[107]	coref	16-16[0_107]
15-21	2025-2031	errors	abstract[107]	giv[107]	_	_
15-22	2032-2038	during	abstract[107]	giv[107]	_	_
15-23	2039-2048	canonical	abstract[107]|event[108]	giv[107]|giv[108]	coref	16-18[0_108]
15-24	2049-2060	replication	abstract[107]|event[108]	giv[107]|giv[108]	_	_
15-25	2061-2062	,	_	_	_	_
15-26	2063-2066	and	_	_	_	_
15-27	2067-2072	those	_	_	_	_
15-28	2073-2080	induced	_	_	_	_
15-29	2081-2083	in	_	_	_	_
15-30	2084-2095	association	abstract[109]	giv[109]	coref	15-37[112_109]
15-31	2096-2100	with	abstract[109]	giv[109]	_	_
15-32	2101-2130	replication-stress-associated	abstract[109]|abstract|abstract[111]	giv[109]|giv|giv[111]	coref	17-13[0_111]
15-33	2131-2135	DSBs	abstract[109]|abstract[111]	giv[109]|giv[111]	_	_
15-34	2136-2140	that	abstract[109]|abstract[111]	giv[109]|giv[111]	_	_
15-35	2141-2151	accumulate	abstract[109]|abstract[111]	giv[109]|giv[111]	_	_
15-36	2152-2154	in	abstract[109]|abstract[111]	giv[109]|giv[111]	_	_
15-37	2155-2166	association	abstract[109]|abstract[111]|abstract[112]	giv[109]|giv[111]|giv[112]	coref	17-11[120_112]
15-38	2167-2171	with	abstract[109]|abstract[111]|abstract[112]	giv[109]|giv[111]|giv[112]	_	_
15-39	2172-2179	genomic	abstract[109]|abstract[111]|abstract[112]|abstract[113]	giv[109]|giv[111]|giv[112]|giv[113]	coref	17-15[123_113]
15-40	2180-2195	destabilization	abstract[109]|abstract[111]|abstract[112]|abstract[113]	giv[109]|giv[111]|giv[112]|giv[113]	_	_
15-41	2196-2197	.	_	_	_	_

#Text=Unexpectedly , the former type is relatively rare even in MMR-deficient cells that cannot correct errors during replication .
16-1	2198-2210	Unexpectedly	_	_	_	_
16-2	2211-2212	,	_	_	_	_
16-3	2213-2216	the	abstract[114]	new[114]	_	_
16-4	2217-2223	former	abstract[114]	new[114]	_	_
16-5	2224-2228	type	abstract[114]	new[114]	_	_
16-6	2229-2231	is	_	_	_	_
16-7	2232-2242	relatively	_	_	_	_
16-8	2243-2247	rare	_	_	_	_
16-9	2248-2252	even	animal[115]	giv[115]	coref	17-18[124_115]
16-10	2253-2255	in	animal[115]	giv[115]	_	_
16-11	2256-2269	MMR-deficient	animal[115]	giv[115]	_	_
16-12	2270-2275	cells	animal[115]	giv[115]	_	_
16-13	2276-2280	that	animal[115]	giv[115]	_	_
16-14	2281-2287	cannot	animal[115]	giv[115]	_	_
16-15	2288-2295	correct	animal[115]	giv[115]	_	_
16-16	2296-2302	errors	animal[115]|abstract	giv[115]|giv	coref	26-24[164_0]
16-17	2303-2309	during	animal[115]	giv[115]	_	_
16-18	2310-2321	replication	animal[115]|event	giv[115]|giv	coref	35-21
16-19	2322-2323	.	_	_	_	_

#Text=By contrast , in the latter , hypermutation occurs in association with DSBs and genomic destabilization in barely replicating cells (
17-1	2324-2326	By	_	_	_	_
17-2	2327-2335	contrast	_	_	_	_
17-3	2336-2337	,	_	_	_	_
17-4	2338-2340	in	_	_	_	_
17-5	2341-2344	the	time[118]	new[118]	_	_
17-6	2345-2351	latter	time[118]	new[118]	_	_
17-7	2352-2353	,	_	_	_	_
17-8	2354-2367	hypermutation	abstract	giv	_	_
17-9	2368-2374	occurs	_	_	_	_
17-10	2375-2377	in	_	_	_	_
17-11	2378-2389	association	abstract[120]	giv[120]	_	_
17-12	2390-2394	with	abstract[120]	giv[120]	_	_
17-13	2395-2399	DSBs	abstract[120]|abstract|abstract[122]	giv[120]|giv|giv[122]	coref|coref	17-13[122_0]|24-3[142_122]
17-14	2400-2403	and	abstract[120]|abstract[122]	giv[120]|giv[122]	_	_
17-15	2404-2411	genomic	abstract[120]|abstract[122]|abstract[123]	giv[120]|giv[122]|giv[123]	coref	27-20[173_123]
17-16	2412-2427	destabilization	abstract[120]|abstract[122]|abstract[123]	giv[120]|giv[122]|giv[123]	_	_
17-17	2428-2430	in	_	_	_	_
17-18	2431-2437	barely	animal[124]	giv[124]	coref	30-1[184_124]
17-19	2438-2449	replicating	animal[124]	giv[124]	_	_
17-20	2450-2455	cells	animal[124]	giv[124]	_	_
17-21	2456-2457	(	_	_	_	_

#Text=Figure 1
18-1	2458-2464	Figure	abstract[125]	new[125]	coref	21-1[134_125]
18-2	2465-2466	1	abstract[125]	new[125]	_	_

#Text=) .
19-1	2467-2468	)	_	_	_	_
19-2	2469-2470	.	_	_	_	_

#Text=Importantly , cancer-driver mutations arise during the latter ; the induced mutations include base substitutions , small insertions and deletions , and large deletions of entire genes (
20-1	2471-2482	Importantly	_	_	_	_
20-2	2483-2484	,	_	_	_	_
20-3	2485-2498	cancer-driver	abstract[126]	giv[126]	coref	20-10[127_126]
20-4	2499-2508	mutations	abstract[126]	giv[126]	_	_
20-5	2509-2514	arise	_	_	_	_
20-6	2515-2521	during	_	_	_	_
20-7	2522-2525	the	_	_	_	_
20-8	2526-2532	latter	_	_	_	_
20-9	2533-2534	;	_	_	_	_
20-10	2535-2538	the	abstract[127]	giv[127]	coref	23-5[0_127]
20-11	2539-2546	induced	abstract[127]	giv[127]	_	_
20-12	2547-2556	mutations	abstract[127]	giv[127]	_	_
20-13	2557-2564	include	_	_	_	_
20-14	2565-2569	base	place|abstract[129]	new|new[129]	_	_
20-15	2570-2583	substitutions	abstract[129]	new[129]	_	_
20-16	2584-2585	,	_	_	_	_
20-17	2586-2591	small	event[130]	new[130]	_	_
20-18	2592-2602	insertions	event[130]	new[130]	_	_
20-19	2603-2606	and	_	_	_	_
20-20	2607-2616	deletions	event	new	_	_
20-21	2617-2618	,	_	_	_	_
20-22	2619-2622	and	_	_	_	_
20-23	2623-2628	large	event[132]	new[132]	coref	36-36[0_132]
20-24	2629-2638	deletions	event[132]	new[132]	_	_
20-25	2639-2641	of	event[132]	new[132]	_	_
20-26	2642-2648	entire	event[132]|abstract[133]	new[132]|new[133]	_	_
20-27	2649-2654	genes	event[132]|abstract[133]	new[132]|new[133]	_	_
20-28	2655-2656	(	_	_	_	_

#Text=Figure 1
21-1	2657-2663	Figure	abstract[134]	giv[134]	_	_
21-2	2664-2665	1	abstract[134]	giv[134]	_	_

#Text=) .
22-1	2666-2667	)	_	_	_	_
22-2	2668-2669	.	_	_	_	_

#Text=The mechanisms responsible for mutations in this context are not clear , probably because of the presence of repair systems and other related polymerases ( Table 1 ) .
23-1	2670-2673	The	abstract[135]	new[135]	_	_
23-2	2674-2684	mechanisms	abstract[135]	new[135]	_	_
23-3	2685-2696	responsible	abstract[135]	new[135]	_	_
23-4	2697-2700	for	abstract[135]	new[135]	_	_
23-5	2701-2710	mutations	abstract[135]|abstract	new[135]|giv	coref	27-4
23-6	2711-2713	in	abstract[135]	new[135]	_	_
23-7	2714-2718	this	abstract[135]|abstract[137]	new[135]|new[137]	_	_
23-8	2719-2726	context	abstract[135]|abstract[137]	new[135]|new[137]	_	_
23-9	2727-2730	are	_	_	_	_
23-10	2731-2734	not	_	_	_	_
23-11	2735-2740	clear	_	_	_	_
23-12	2741-2742	,	_	_	_	_
23-13	2743-2751	probably	abstract[138]	new[138]	_	_
23-14	2752-2759	because	abstract[138]	new[138]	_	_
23-15	2760-2762	of	abstract[138]	new[138]	_	_
23-16	2763-2766	the	abstract[138]	new[138]	_	_
23-17	2767-2775	presence	abstract[138]	new[138]	_	_
23-18	2776-2778	of	abstract[138]	new[138]	_	_
23-19	2779-2785	repair	abstract[138]|abstract|abstract[140]	new[138]|giv|new[140]	coref|coref	39-10[232_0]|43-22[248_140]
23-20	2786-2793	systems	abstract[138]|abstract[140]	new[138]|new[140]	_	_
23-21	2794-2797	and	abstract[138]	new[138]	_	_
23-22	2798-2803	other	abstract[138]|substance[141]	new[138]|giv[141]	coref	24-20[146_141]
23-23	2804-2811	related	abstract[138]|substance[141]	new[138]|giv[141]	_	_
23-24	2812-2823	polymerases	abstract[138]|substance[141]	new[138]|giv[141]	_	_
23-25	2824-2825	(	_	_	_	_
23-26	2826-2831	Table	_	_	_	_
23-27	2832-2833	1	_	_	_	_
23-28	2834-2835	)	_	_	_	_
23-29	2836-2837	.	_	_	_	_

#Text=Indeed , these DSBs are generally a target of homologous recombination ( HR ) , which does not involve high-fidelity polymerases ( pols ) δ and ε .
24-1	2838-2844	Indeed	_	_	_	_
24-2	2845-2846	,	_	_	_	_
24-3	2847-2852	these	abstract[142]	giv[142]	coref	24-6[143_142]
24-4	2853-2857	DSBs	abstract[142]	giv[142]	_	_
24-5	2858-2861	are	_	_	_	_
24-6	2862-2871	generally	abstract[143]	giv[143]	coref	32-11[200_143]
24-7	2872-2873	a	abstract[143]	giv[143]	_	_
24-8	2874-2880	target	abstract[143]	giv[143]	_	_
24-9	2881-2883	of	abstract[143]	giv[143]	_	_
24-10	2884-2894	homologous	abstract[143]|event[144]	giv[143]|new[144]	_	_
24-11	2895-2908	recombination	abstract[143]|event[144]	giv[143]|new[144]	_	_
24-12	2909-2910	(	_	_	_	_
24-13	2911-2913	HR	abstract	new	coref	35-12
24-14	2914-2915	)	_	_	_	_
24-15	2916-2917	,	_	_	_	_
24-16	2918-2923	which	_	_	_	_
24-17	2924-2928	does	_	_	_	_
24-18	2929-2932	not	_	_	_	_
24-19	2933-2940	involve	_	_	_	_
24-20	2941-2954	high-fidelity	substance[146]	giv[146]	coref	25-3[152_146]
24-21	2955-2966	polymerases	substance[146]	giv[146]	_	_
24-22	2967-2968	(	_	_	_	_
24-23	2969-2973	pols	abstract	new	_	_
24-24	2974-2975	)	_	_	_	_
24-25	2976-2977	δ	_	_	_	_
24-26	2978-2981	and	_	_	_	_
24-27	2982-2983	ε	abstract	giv	_	_
24-28	2984-2985	.	_	_	_	_

#Text=Instead , low-fidelity translesion synthesis ( TLS ) polymerases δ , κ , and θ , which synthesize DNA over lesioned templates , are highly expressed .
25-1	2986-2993	Instead	_	_	_	_
25-2	2994-2995	,	_	_	_	_
25-3	2996-3008	low-fidelity	abstract[150]|substance[152]|substance[153]	new[150]|giv[152]|giv[153]	appos|coref|coref	25-7[0_150]|25-3[153_152]|26-15[162_153]
25-4	3009-3020	translesion	abstract|abstract[150]|substance[152]|substance[153]	new|new[150]|giv[152]|giv[153]	coref	26-29
25-5	3021-3030	synthesis	abstract[150]|substance[152]|substance[153]	new[150]|giv[152]|giv[153]	_	_
25-6	3031-3032	(	substance[152]|substance[153]	giv[152]|giv[153]	_	_
25-7	3033-3036	TLS	abstract|substance[152]|substance[153]	giv|giv[152]|giv[153]	coref	26-11[161_0]
25-8	3037-3038	)	substance[152]|substance[153]	giv[152]|giv[153]	_	_
25-9	3039-3050	polymerases	substance[152]|substance[153]	giv[152]|giv[153]	_	_
25-10	3051-3052	δ	substance[152]|substance[153]	giv[152]|giv[153]	_	_
25-11	3053-3054	,	substance[152]|substance[153]	giv[152]|giv[153]	_	_
25-12	3055-3056	κ	substance[152]|substance[153]|abstract	giv[152]|giv[153]|new	_	_
25-13	3057-3058	,	substance[152]|substance[153]	giv[152]|giv[153]	_	_
25-14	3059-3062	and	substance[152]|substance[153]	giv[152]|giv[153]	_	_
25-15	3063-3064	θ	substance[152]|substance[153]|abstract	giv[152]|giv[153]|new	_	_
25-16	3065-3066	,	substance[152]|substance[153]	giv[152]|giv[153]	_	_
25-17	3067-3072	which	substance[152]|substance[153]	giv[152]|giv[153]	_	_
25-18	3073-3083	synthesize	substance[152]|substance[153]	giv[152]|giv[153]	_	_
25-19	3084-3087	DNA	substance[152]|substance[153]|abstract	giv[152]|giv[153]|giv	coref	26-11
25-20	3088-3092	over	substance[152]|substance[153]	giv[152]|giv[153]	_	_
25-21	3093-3101	lesioned	substance[152]|substance[153]|object[157]	giv[152]|giv[153]|new[157]	ana	27-13[0_157]
25-22	3102-3111	templates	substance[152]|substance[153]|object[157]	giv[152]|giv[153]|new[157]	_	_
25-23	3112-3113	,	_	_	_	_
25-24	3114-3117	are	_	_	_	_
25-25	3118-3124	highly	_	_	_	_
25-26	3125-3134	expressed	_	_	_	_
25-27	3135-3136	.	_	_	_	_

#Text=Thus , the higher mutation rates are probably due to DNA synthesis performed by these polymerases , which lack proofreading activity , and the errors probably occur during translesion synthesis .
26-1	3137-3141	Thus	_	_	_	_
26-2	3142-3143	,	_	_	_	_
26-3	3144-3147	the	abstract[159]	giv[159]	_	_
26-4	3148-3154	higher	abstract[159]	giv[159]	_	_
26-5	3155-3163	mutation	abstract|abstract[159]	giv|giv[159]	_	_
26-6	3164-3169	rates	abstract[159]	giv[159]	_	_
26-7	3170-3173	are	_	_	_	_
26-8	3174-3182	probably	_	_	_	_
26-9	3183-3186	due	_	_	_	_
26-10	3187-3189	to	_	_	_	_
26-11	3190-3193	DNA	abstract|abstract[161]	giv|giv[161]	coref|coref	26-29[166_161]|43-22
26-12	3194-3203	synthesis	abstract[161]	giv[161]	_	_
26-13	3204-3213	performed	abstract[161]	giv[161]	_	_
26-14	3214-3216	by	abstract[161]	giv[161]	_	_
26-15	3217-3222	these	abstract[161]|substance[162]	giv[161]|giv[162]	_	_
26-16	3223-3234	polymerases	abstract[161]|substance[162]	giv[161]|giv[162]	_	_
26-17	3235-3236	,	abstract[161]|substance[162]	giv[161]|giv[162]	_	_
26-18	3237-3242	which	abstract[161]|substance[162]	giv[161]|giv[162]	_	_
26-19	3243-3247	lack	abstract[161]|substance[162]	giv[161]|giv[162]	_	_
26-20	3248-3260	proofreading	abstract[161]|substance[162]|abstract[163]	giv[161]|giv[162]|new[163]	_	_
26-21	3261-3269	activity	abstract[161]|substance[162]|abstract[163]	giv[161]|giv[162]|new[163]	_	_
26-22	3270-3271	,	_	_	_	_
26-23	3272-3275	and	_	_	_	_
26-24	3276-3279	the	abstract[164]	giv[164]	_	_
26-25	3280-3286	errors	abstract[164]	giv[164]	_	_
26-26	3287-3295	probably	_	_	_	_
26-27	3296-3301	occur	_	_	_	_
26-28	3302-3308	during	_	_	_	_
26-29	3309-3320	translesion	abstract|abstract[166]	giv|giv[166]	_	_
26-30	3321-3330	synthesis	abstract[166]	giv[166]	_	_
26-31	3331-3332	.	_	_	_	_

#Text=Thus , while mutations are strongly suppressed during normal cell division , they increase after replication-stress-associated DSB accumulation and genomic destabilization .
27-1	3333-3337	Thus	_	_	_	_
27-2	3338-3339	,	_	_	_	_
27-3	3340-3345	while	_	_	_	_
27-4	3346-3355	mutations	abstract	giv	coref	28-10[176_0]
27-5	3356-3359	are	_	_	_	_
27-6	3360-3368	strongly	_	_	_	_
27-7	3369-3379	suppressed	_	_	_	_
27-8	3380-3386	during	_	_	_	_
27-9	3387-3393	normal	abstract[169]	giv[169]	_	_
27-10	3394-3398	cell	object|abstract[169]	giv|giv[169]	_	_
27-11	3399-3407	division	abstract[169]	giv[169]	_	_
27-12	3408-3409	,	_	_	_	_
27-13	3410-3414	they	object	giv	_	_
27-14	3415-3423	increase	_	_	_	_
27-15	3424-3429	after	_	_	_	_
27-16	3430-3459	replication-stress-associated	event[172]	new[172]	coref	47-13[272_172]
27-17	3460-3463	DSB	abstract|event[172]	new|new[172]	coref	39-12
27-18	3464-3476	accumulation	event[172]	new[172]	_	_
27-19	3477-3480	and	_	_	_	_
27-20	3481-3488	genomic	abstract[173]	giv[173]	coref	29-8[182_173]
27-21	3489-3504	destabilization	abstract[173]	giv[173]	_	_
27-22	3505-3506	.	_	_	_	_

#Text=Given that most cancers ultimately develop genomic instability , these mutations are most likely the ones that contribute to cancer progression .
28-1	3507-3512	Given	abstract[177]	giv[177]	coref|coref	28-1[177_176]|43-19[245_177]
28-2	3513-3517	that	abstract[177]	giv[177]	_	_
28-3	3518-3522	most	abstract[174]|abstract[177]	new[174]|giv[177]	coref	31-12[196_174]
28-4	3523-3530	cancers	abstract[174]|abstract[177]	new[174]|giv[177]	_	_
28-5	3531-3541	ultimately	abstract[177]	giv[177]	_	_
28-6	3542-3549	develop	abstract[177]	giv[177]	_	_
28-7	3550-3557	genomic	abstract[175]|abstract[177]	giv[175]|giv[177]	coref	30-10[187_175]
28-8	3558-3569	instability	abstract[175]|abstract[177]	giv[175]|giv[177]	_	_
28-9	3570-3571	,	abstract[177]	giv[177]	_	_
28-10	3572-3577	these	abstract[176]|abstract[177]	giv[176]|giv[177]	_	_
28-11	3578-3587	mutations	abstract[176]|abstract[177]	giv[176]|giv[177]	_	_
28-12	3588-3591	are	abstract[177]	giv[177]	_	_
28-13	3592-3596	most	abstract[177]	giv[177]	_	_
28-14	3597-3603	likely	abstract[177]	giv[177]	_	_
28-15	3604-3607	the	abstract[177]	giv[177]	_	_
28-16	3608-3612	ones	abstract[177]	giv[177]	_	_
28-17	3613-3617	that	abstract[177]	giv[177]	_	_
28-18	3618-3628	contribute	abstract[177]	giv[177]	_	_
28-19	3629-3631	to	abstract[177]	giv[177]	_	_
28-20	3632-3638	cancer	abstract[177]|abstract|event[179]	giv[177]|giv|new[179]	coref	30-2
28-21	3639-3650	progression	abstract[177]|event[179]	giv[177]|new[179]	_	_
28-22	3651-3652	.	_	_	_	_

#Text=2.3. Senescence-Associated Increase in the Risk of Genomic Destabilization
29-1	3653-3657	2.3.	_	_	_	_
29-2	3658-3679	Senescence-Associated	abstract[180]	new[180]	_	_
29-3	3680-3688	Increase	abstract[180]	new[180]	_	_
29-4	3689-3691	in	abstract[180]	new[180]	_	_
29-5	3692-3695	the	abstract[180]|abstract[181]	new[180]|new[181]	coref	45-13[260_181]
29-6	3696-3700	Risk	abstract[180]|abstract[181]	new[180]|new[181]	_	_
29-7	3701-3703	of	abstract[180]|abstract[181]	new[180]|new[181]	_	_
29-8	3704-3711	Genomic	abstract[180]|abstract[181]|abstract[182]	new[180]|new[181]|giv[182]	coref	44-7[251_182]
29-9	3712-3727	Destabilization	abstract[180]|abstract[181]|abstract[182]	new[180]|new[181]|giv[182]	_	_

#Text=Most cancer cells develop one of two forms of genomic instability : chromosomal instability ( CIN ) or microsatellite instability ( MSI ) .
30-1	3728-3732	Most	animal[184]	giv[184]	coref	44-10[252_184]
30-2	3733-3739	cancer	abstract|animal[184]	giv|giv[184]	coref	45-15
30-3	3740-3745	cells	animal[184]	giv[184]	_	_
30-4	3746-3753	develop	_	_	_	_
30-5	3754-3757	one	abstract[185]	new[185]	_	_
30-6	3758-3760	of	abstract[185]	new[185]	_	_
30-7	3761-3764	two	abstract[185]|abstract[186]	new[185]|new[186]	_	_
30-8	3765-3770	forms	abstract[185]|abstract[186]	new[185]|new[186]	_	_
30-9	3771-3773	of	abstract[185]|abstract[186]	new[185]|new[186]	_	_
30-10	3774-3781	genomic	abstract[185]|abstract[186]|abstract[187]	new[185]|new[186]|giv[187]	appos	30-13[188_187]
30-11	3782-3793	instability	abstract[185]|abstract[186]|abstract[187]	new[185]|new[186]|giv[187]	_	_
30-12	3794-3795	:	_	_	_	_
30-13	3796-3807	chromosomal	abstract[188]	giv[188]	appos	30-16[0_188]
30-14	3808-3819	instability	abstract[188]	giv[188]	_	_
30-15	3820-3821	(	_	_	_	_
30-16	3822-3825	CIN	abstract	giv	appos	30-19[191_0]
30-17	3826-3827	)	_	_	_	_
30-18	3828-3830	or	_	_	_	_
30-19	3831-3845	microsatellite	abstract|abstract[191]	new|giv[191]	appos	30-22[0_191]
30-20	3846-3857	instability	abstract[191]	giv[191]	_	_
30-21	3858-3859	(	_	_	_	_
30-22	3860-3863	MSI	abstract	giv	coref	31-1
30-23	3864-3865	)	_	_	_	_
30-24	3866-3867	.	_	_	_	_

#Text=CIN is the most frequent , but MSI usually arises in MMR-deficient cancers ( Table 1 ) .
31-1	3868-3871	CIN	abstract	giv	coref	31-8
31-2	3872-3874	is	_	_	_	_
31-3	3875-3878	the	_	_	_	_
31-4	3879-3883	most	_	_	_	_
31-5	3884-3892	frequent	_	_	_	_
31-6	3893-3894	,	_	_	_	_
31-7	3895-3898	but	_	_	_	_
31-8	3899-3902	MSI	abstract	giv	coref	32-4[198_0]
31-9	3903-3910	usually	_	_	_	_
31-10	3911-3917	arises	_	_	_	_
31-11	3918-3920	in	_	_	_	_
31-12	3921-3934	MMR-deficient	object|abstract[196]	new|giv[196]	coref	43-1[240_196]
31-13	3935-3942	cancers	abstract[196]	giv[196]	_	_
31-14	3943-3944	(	_	_	_	_
31-15	3945-3950	Table	_	_	_	_
31-16	3951-3952	1	_	_	_	_
31-17	3953-3954	)	_	_	_	_
31-18	3955-3956	.	_	_	_	_

#Text=The induction of both CIN and MSI is triggered by replication-stress-associated DSBs (
32-1	3957-3960	The	event[197]	new[197]	_	_
32-2	3961-3970	induction	event[197]	new[197]	_	_
32-3	3971-3973	of	event[197]	new[197]	_	_
32-4	3974-3978	both	event[197]|abstract[198]	new[197]|giv[198]	coref	32-7[0_198]
32-5	3979-3982	CIN	event[197]|abstract[198]	new[197]|giv[198]	_	_
32-6	3983-3986	and	event[197]	new[197]	_	_
32-7	3987-3990	MSI	event[197]|abstract	new[197]|giv	coref	35-1
32-8	3991-3993	is	_	_	_	_
32-9	3994-4003	triggered	_	_	_	_
32-10	4004-4006	by	_	_	_	_
32-11	4007-4036	replication-stress-associated	abstract[200]	giv[200]	coref	35-5[203_200]
32-12	4037-4041	DSBs	abstract[200]	giv[200]	_	_
32-13	4042-4043	(	_	_	_	_

#Text=Figure 2
33-1	4044-4050	Figure	abstract[201]	new[201]	coref	40-1[233_201]
33-2	4051-4052	2	abstract[201]	new[201]	_	_

#Text=) .
34-1	4053-4054	)	_	_	_	_
34-2	4055-4056	.	_	_	_	_

#Text=CIN often occurs when such DSBs are not effectively repaired by HR , that is , when DSBs arising during replication are carried over into the following G1 phase at a time when HR is not functional .
35-1	4057-4060	CIN	abstract	giv	coref	37-4
35-2	4061-4066	often	_	_	_	_
35-3	4067-4073	occurs	_	_	_	_
35-4	4074-4078	when	_	_	_	_
35-5	4079-4083	such	abstract[203]	giv[203]	coref	35-18[205_203]
35-6	4084-4088	DSBs	abstract[203]	giv[203]	_	_
35-7	4089-4092	are	_	_	_	_
35-8	4093-4096	not	_	_	_	_
35-9	4097-4108	effectively	_	_	_	_
35-10	4109-4117	repaired	_	_	_	_
35-11	4118-4120	by	_	_	_	_
35-12	4121-4123	HR	abstract	giv	coref	35-34
35-13	4124-4125	,	_	_	_	_
35-14	4126-4130	that	_	_	_	_
35-15	4131-4133	is	_	_	_	_
35-16	4134-4135	,	_	_	_	_
35-17	4136-4140	when	_	_	_	_
35-18	4141-4145	DSBs	abstract[205]	giv[205]	coref	36-3[211_205]
35-19	4146-4153	arising	abstract[205]	giv[205]	_	_
35-20	4154-4160	during	abstract[205]	giv[205]	_	_
35-21	4161-4172	replication	abstract[205]|event	giv[205]|giv	_	_
35-22	4173-4176	are	_	_	_	_
35-23	4177-4184	carried	_	_	_	_
35-24	4185-4189	over	_	_	_	_
35-25	4190-4194	into	_	_	_	_
35-26	4195-4198	the	abstract[208]	new[208]	_	_
35-27	4199-4208	following	abstract[208]	new[208]	_	_
35-28	4209-4211	G1	abstract|abstract[208]	new|new[208]	_	_
35-29	4212-4217	phase	abstract[208]	new[208]	_	_
35-30	4218-4220	at	_	_	_	_
35-31	4221-4222	a	time[209]	new[209]	_	_
35-32	4223-4227	time	time[209]	new[209]	_	_
35-33	4228-4232	when	time[209]	new[209]	_	_
35-34	4233-4235	HR	time[209]|abstract	new[209]|giv	_	_
35-35	4236-4238	is	time[209]	new[209]	_	_
35-36	4239-4242	not	time[209]	new[209]	_	_
35-37	4243-4253	functional	time[209]	new[209]	_	_
35-38	4254-4255	.	_	_	_	_

#Text=Consequently , the DSBs are often erroneously ligated by non-homologous end joining ( NHEJ ) with topologically incorrect broken ends , resulting in a background that causes CIN-associated chromosomal alterations such as chromosomal translocations , deletions , and rearrangements .
36-1	4256-4268	Consequently	_	_	_	_
36-2	4269-4270	,	_	_	_	_
36-3	4271-4274	the	abstract[211]	giv[211]	coref	37-7[224_211]
36-4	4275-4279	DSBs	abstract[211]	giv[211]	_	_
36-5	4280-4283	are	_	_	_	_
36-6	4284-4289	often	_	_	_	_
36-7	4290-4301	erroneously	_	_	_	_
36-8	4302-4309	ligated	_	_	_	_
36-9	4310-4312	by	_	_	_	_
36-10	4313-4327	non-homologous	event[213]	new[213]	coref	37-15[226_213]
36-11	4328-4331	end	event|event[213]	new|new[213]	coref	37-16
36-12	4332-4339	joining	event[213]	new[213]	_	_
36-13	4340-4341	(	_	_	_	_
36-14	4342-4346	NHEJ	abstract	new	_	_
36-15	4347-4348	)	_	_	_	_
36-16	4349-4353	with	_	_	_	_
36-17	4354-4367	topologically	object[215]	new[215]	_	_
36-18	4368-4377	incorrect	object[215]	new[215]	_	_
36-19	4378-4384	broken	object[215]	new[215]	_	_
36-20	4385-4389	ends	object[215]	new[215]	_	_
36-21	4390-4391	,	_	_	_	_
36-22	4392-4401	resulting	_	_	_	_
36-23	4402-4404	in	_	_	_	_
36-24	4405-4406	a	abstract[216]	new[216]	_	_
36-25	4407-4417	background	abstract[216]	new[216]	_	_
36-26	4418-4422	that	abstract[216]	new[216]	_	_
36-27	4423-4429	causes	abstract[216]	new[216]	_	_
36-28	4430-4444	CIN-associated	abstract[216]|abstract|abstract[218]	new[216]|new|new[218]	_	_
36-29	4445-4456	chromosomal	abstract[216]|abstract[218]	new[216]|new[218]	_	_
36-30	4457-4468	alterations	abstract[216]|abstract[218]	new[216]|new[218]	_	_
36-31	4469-4473	such	abstract[216]|abstract[218]	new[216]|new[218]	_	_
36-32	4474-4476	as	abstract[216]|abstract[218]	new[216]|new[218]	_	_
36-33	4477-4488	chromosomal	abstract[216]|abstract[218]|abstract[219]	new[216]|new[218]|new[219]	_	_
36-34	4489-4503	translocations	abstract[216]|abstract[218]|abstract[219]	new[216]|new[218]|new[219]	_	_
36-35	4504-4505	,	abstract[216]|abstract[218]	new[216]|new[218]	_	_
36-36	4506-4515	deletions	abstract[216]|abstract[218]|event	new[216]|new[218]|giv	_	_
36-37	4516-4517	,	abstract[216]|abstract[218]	new[216]|new[218]	_	_
36-38	4518-4521	and	abstract[216]|abstract[218]	new[216]|new[218]	_	_
36-39	4522-4536	rearrangements	abstract[216]|abstract[218]|event	new[216]|new[218]|new	_	_
36-40	4537-4538	.	_	_	_	_

#Text=By contrast , MSI arises when those DSBs are effectively but erroneously repaired by microhomology-mediated end joining ( MMEJ ; also known as alternative end joining ) (
37-1	4539-4541	By	_	_	_	_
37-2	4542-4550	contrast	abstract	new	_	_
37-3	4551-4552	,	_	_	_	_
37-4	4553-4556	MSI	abstract	giv	coref	39-5
37-5	4557-4563	arises	_	_	_	_
37-6	4564-4568	when	_	_	_	_
37-7	4569-4574	those	abstract[224]	giv[224]	coref	42-10[236_224]
37-8	4575-4579	DSBs	abstract[224]	giv[224]	_	_
37-9	4580-4583	are	_	_	_	_
37-10	4584-4595	effectively	_	_	_	_
37-11	4596-4599	but	_	_	_	_
37-12	4600-4611	erroneously	_	_	_	_
37-13	4612-4620	repaired	_	_	_	_
37-14	4621-4623	by	_	_	_	_
37-15	4624-4646	microhomology-mediated	event[226]	giv[226]	_	_
37-16	4647-4650	end	event|event[226]	giv|giv[226]	coref	37-25
37-17	4651-4658	joining	event[226]	giv[226]	_	_
37-18	4659-4660	(	_	_	_	_
37-19	4661-4665	MMEJ	abstract	new	_	_
37-20	4666-4667	;	_	_	_	_
37-21	4668-4672	also	_	_	_	_
37-22	4673-4678	known	_	_	_	_
37-23	4679-4681	as	_	_	_	_
37-24	4682-4693	alternative	_	_	_	_
37-25	4694-4697	end	event	giv	_	_
37-26	4698-4705	joining	_	_	_	_
37-27	4706-4707	)	_	_	_	_
37-28	4708-4709	(	_	_	_	_

#Text=Figure 3
38-1	4710-4716	Figure	abstract[229]	new[229]	_	_
38-2	4717-4718	3	abstract[229]	new[229]	_	_

#Text=) , during which CIN is suppressed because of the resultant DSB repair (
39-1	4719-4720	)	_	_	_	_
39-2	4721-4722	,	_	_	_	_
39-3	4723-4729	during	_	_	_	_
39-4	4730-4735	which	_	_	_	_
39-5	4736-4739	CIN	abstract	giv	coref	42-3[234_0]
39-6	4740-4742	is	_	_	_	_
39-7	4743-4753	suppressed	_	_	_	_
39-8	4754-4761	because	_	_	_	_
39-9	4762-4764	of	_	_	_	_
39-10	4765-4768	the	abstract[232]	giv[232]	coref	42-18[238_232]
39-11	4769-4778	resultant	abstract[232]	giv[232]	_	_
39-12	4779-4782	DSB	abstract|abstract[232]	giv|giv[232]	coref	43-10
39-13	4783-4789	repair	abstract[232]	giv[232]	_	_
39-14	4790-4791	(	_	_	_	_

#Text=Figure 2
40-1	4792-4798	Figure	abstract[233]	giv[233]	_	_
40-2	4799-4800	2	abstract[233]	giv[233]	_	_

#Text=) .
41-1	4801-4802	)	_	_	_	_
41-2	4803-4804	.	_	_	_	_

#Text=Thus , both CIN and MSI are triggered by replication-stress-associated DSBs and arise due to abnormalities in the repair of these lesions .
42-1	4805-4809	Thus	_	_	_	_
42-2	4810-4811	,	_	_	_	_
42-3	4812-4816	both	abstract[234]	giv[234]	coref	42-6[0_234]
42-4	4817-4820	CIN	abstract[234]	giv[234]	_	_
42-5	4821-4824	and	_	_	_	_
42-6	4825-4828	MSI	abstract	giv	coref	43-4[241_0]
42-7	4829-4832	are	_	_	_	_
42-8	4833-4842	triggered	_	_	_	_
42-9	4843-4845	by	_	_	_	_
42-10	4846-4875	replication-stress-associated	abstract[236]	giv[236]	coref	46-3[261_236]
42-11	4876-4880	DSBs	abstract[236]	giv[236]	_	_
42-12	4881-4884	and	_	_	_	_
42-13	4885-4890	arise	_	_	_	_
42-14	4891-4894	due	_	_	_	_
42-15	4895-4897	to	_	_	_	_
42-16	4898-4911	abnormalities	abstract[237]	new[237]	coref	43-8[242_237]
42-17	4912-4914	in	abstract[237]	new[237]	_	_
42-18	4915-4918	the	abstract[237]|abstract[238]	new[237]|giv[238]	coref	43-10[244_238]
42-19	4919-4925	repair	abstract[237]|abstract[238]	new[237]|giv[238]	_	_
42-20	4926-4928	of	abstract[237]|abstract[238]	new[237]|giv[238]	_	_
42-21	4929-4934	these	abstract[237]|abstract[238]|object[239]	new[237]|giv[238]|new[239]	_	_
42-22	4935-4942	lesions	abstract[237]|abstract[238]|object[239]	new[237]|giv[238]|new[239]	_	_
42-23	4943-4944	.	_	_	_	_

#Text=Most cancers develop genomic instability due to abnormalities in DSB repair ; paradoxically , however , most lack background mutations in DNA repair systems .
43-1	4945-4949	Most	abstract[240]	giv[240]	_	_
43-2	4950-4957	cancers	abstract[240]	giv[240]	_	_
43-3	4958-4965	develop	_	_	_	_
43-4	4966-4973	genomic	abstract[241]	giv[241]	_	_
43-5	4974-4985	instability	abstract[241]	giv[241]	_	_
43-6	4986-4989	due	_	_	_	_
43-7	4990-4992	to	_	_	_	_
43-8	4993-5006	abnormalities	abstract[242]	giv[242]	_	_
43-9	5007-5009	in	abstract[242]	giv[242]	_	_
43-10	5010-5013	DSB	abstract[242]|abstract|abstract[244]	giv[242]|giv|giv[244]	coref|coref	43-22[247_244]|47-13
43-11	5014-5020	repair	abstract[242]|abstract[244]	giv[242]|giv[244]	_	_
43-12	5021-5022	;	_	_	_	_
43-13	5023-5036	paradoxically	_	_	_	_
43-14	5037-5038	,	_	_	_	_
43-15	5039-5046	however	_	_	_	_
43-16	5047-5048	,	_	_	_	_
43-17	5049-5053	most	_	_	_	_
43-18	5054-5058	lack	_	_	_	_
43-19	5059-5069	background	abstract[245]	giv[245]	_	_
43-20	5070-5079	mutations	abstract[245]	giv[245]	_	_
43-21	5080-5082	in	abstract[245]	giv[245]	_	_
43-22	5083-5086	DNA	abstract[245]|abstract|abstract[247]|abstract[248]	giv[245]|giv|giv[247]|giv[248]	ana|coref|coref	44-1[0_247]|44-23|44-22[256_248]
43-23	5087-5093	repair	abstract[245]|abstract[247]|abstract[248]	giv[245]|giv[247]|giv[248]	_	_
43-24	5094-5101	systems	abstract[245]|abstract[248]	giv[245]|giv[248]	_	_
43-25	5102-5103	.	_	_	_	_

#Text=This raises the question of how genomic destabilization occurs even in normal cells , that is , genetically normal cells with functional DNA repair systems .
44-1	5104-5108	This	abstract	giv	coref	44-23[255_0]
44-2	5109-5115	raises	_	_	_	_
44-3	5116-5119	the	abstract[250]	new[250]	_	_
44-4	5120-5128	question	abstract[250]	new[250]	_	_
44-5	5129-5131	of	abstract[250]	new[250]	_	_
44-6	5132-5135	how	abstract[250]	new[250]	_	_
44-7	5136-5143	genomic	abstract[250]|abstract[251]	new[250]|giv[251]	_	_
44-8	5144-5159	destabilization	abstract[250]|abstract[251]	new[250]|giv[251]	_	_
44-9	5160-5166	occurs	abstract[250]	new[250]	_	_
44-10	5167-5171	even	abstract[250]|animal[252]	new[250]|giv[252]	coref	44-15[253_252]
44-11	5172-5174	in	abstract[250]|animal[252]	new[250]|giv[252]	_	_
44-12	5175-5181	normal	abstract[250]|animal[252]	new[250]|giv[252]	_	_
44-13	5182-5187	cells	abstract[250]|animal[252]	new[250]|giv[252]	_	_
44-14	5188-5189	,	abstract[250]|animal[252]	new[250]|giv[252]	_	_
44-15	5190-5194	that	abstract[250]|animal[252]|animal[253]	new[250]|giv[252]|giv[253]	coref	47-5[0_253]
44-16	5195-5197	is	abstract[250]|animal[252]|animal[253]	new[250]|giv[252]|giv[253]	_	_
44-17	5198-5199	,	abstract[250]|animal[252]|animal[253]	new[250]|giv[252]|giv[253]	_	_
44-18	5200-5211	genetically	abstract[250]|animal[252]|animal[253]	new[250]|giv[252]|giv[253]	_	_
44-19	5212-5218	normal	abstract[250]|animal[252]|animal[253]	new[250]|giv[252]|giv[253]	_	_
44-20	5219-5224	cells	abstract[250]|animal[252]|animal[253]	new[250]|giv[252]|giv[253]	_	_
44-21	5225-5229	with	abstract[250]|animal[252]|animal[253]	new[250]|giv[252]|giv[253]	_	_
44-22	5230-5240	functional	abstract[250]|animal[252]|animal[253]|abstract[256]	new[250]|giv[252]|giv[253]|giv[256]	_	_
44-23	5241-5244	DNA	abstract[250]|animal[252]|animal[253]|abstract|abstract[255]|abstract[256]	new[250]|giv[252]|giv[253]|giv|giv[255]|giv[256]	_	_
44-24	5245-5251	repair	abstract[250]|animal[252]|animal[253]|abstract[255]|abstract[256]	new[250]|giv[252]|giv[253]|giv[255]|giv[256]	_	_
44-25	5252-5259	systems	abstract[250]|animal[252]|animal[253]|abstract[256]	new[250]|giv[252]|giv[253]|giv[256]	_	_
44-26	5260-5261	.	_	_	_	_

#Text=This phenomenon is probably associated with age , which is associated with an elevated cancer risk .
45-1	5262-5266	This	abstract[257]	new[257]	_	_
45-2	5267-5277	phenomenon	abstract[257]	new[257]	_	_
45-3	5278-5280	is	_	_	_	_
45-4	5281-5289	probably	_	_	_	_
45-5	5290-5300	associated	_	_	_	_
45-6	5301-5305	with	_	_	_	_
45-7	5306-5309	age	abstract[258]	new[258]	coref	46-10[0_258]
45-8	5310-5311	,	abstract[258]	new[258]	_	_
45-9	5312-5317	which	abstract[258]	new[258]	_	_
45-10	5318-5320	is	abstract[258]	new[258]	_	_
45-11	5321-5331	associated	abstract[258]	new[258]	_	_
45-12	5332-5336	with	abstract[258]	new[258]	_	_
45-13	5337-5339	an	abstract[258]|abstract[260]	new[258]|giv[260]	_	_
45-14	5340-5348	elevated	abstract[258]|abstract[260]	new[258]|giv[260]	_	_
45-15	5349-5355	cancer	abstract[258]|abstract|abstract[260]	new[258]|giv|giv[260]	_	_
45-16	5356-5360	risk	abstract[258]|abstract[260]	new[258]|giv[260]	_	_
45-17	5361-5362	.	_	_	_	_

#Text=Indeed , irreparable DSBs accumulate widely in association with age in vivo and passage in vitro .
46-1	5363-5369	Indeed	_	_	_	_
46-2	5370-5371	,	_	_	_	_
46-3	5372-5383	irreparable	abstract[261]	giv[261]	_	_
46-4	5384-5388	DSBs	abstract[261]	giv[261]	_	_
46-5	5389-5399	accumulate	_	_	_	_
46-6	5400-5406	widely	_	_	_	_
46-7	5407-5409	in	_	_	_	_
46-8	5410-5421	association	abstract[262]	new[262]	_	_
46-9	5422-5426	with	abstract[262]	new[262]	_	_
46-10	5427-5430	age	abstract[262]|abstract	new[262]|giv	_	_
46-11	5431-5433	in	abstract[262]	new[262]	_	_
46-12	5434-5438	vivo	abstract[262]|abstract	new[262]|new	_	_
46-13	5439-5442	and	abstract[262]	new[262]	_	_
46-14	5443-5450	passage	abstract[262]|event[265]	new[262]|new[265]	_	_
46-15	5451-5453	in	abstract[262]|event[265]	new[262]|new[265]	_	_
46-16	5454-5459	vitro	abstract[262]|event[265]|abstract	new[262]|new[265]|new	ana	47-3
46-17	5460-5461	.	_	_	_	_

#Text=Consistent with this , cells often undergo senescence as a consequence of DSB accumulation .
47-1	5462-5472	Consistent	_	_	_	_
47-2	5473-5477	with	_	_	_	_
47-3	5478-5482	this	abstract	giv	_	_
47-4	5483-5484	,	_	_	_	_
47-5	5485-5490	cells	animal	giv	_	_
47-6	5491-5496	often	_	_	_	_
47-7	5497-5504	undergo	_	_	_	_
47-8	5505-5515	senescence	abstract	new	_	_
47-9	5516-5518	as	_	_	_	_
47-10	5519-5520	a	abstract[270]	new[270]	_	_
47-11	5521-5532	consequence	abstract[270]	new[270]	_	_
47-12	5533-5535	of	abstract[270]	new[270]	_	_
47-13	5536-5539	DSB	abstract[270]|abstract|event[272]	new[270]|giv|giv[272]	coref|coref	48-5|48-5[275_272]
47-14	5540-5552	accumulation	abstract[270]|event[272]	new[270]|giv[272]	_	_
47-15	5553-5554	.	_	_	_	_

#Text=Although the reasons for DSB accumulation are not clear , they are likely to include a reduction in histone H2AX , which mediates repair-factor recruitment and is required for genome stability .
48-1	5555-5563	Although	_	_	_	_
48-2	5564-5567	the	abstract[273]	new[273]	ana	48-11[0_273]
48-3	5568-5575	reasons	abstract[273]	new[273]	_	_
48-4	5576-5579	for	abstract[273]	new[273]	_	_
48-5	5580-5583	DSB	abstract[273]|abstract|event[275]	new[273]|giv|giv[275]	_	_
48-6	5584-5596	accumulation	abstract[273]|event[275]	new[273]|giv[275]	_	_
48-7	5597-5600	are	_	_	_	_
48-8	5601-5604	not	_	_	_	_
48-9	5605-5610	clear	_	_	_	_
48-10	5611-5612	,	_	_	_	_
48-11	5613-5617	they	abstract	giv	_	_
48-12	5618-5621	are	_	_	_	_
48-13	5622-5628	likely	_	_	_	_
48-14	5629-5631	to	_	_	_	_
48-15	5632-5639	include	_	_	_	_
48-16	5640-5641	a	abstract[277]	new[277]	_	_
48-17	5642-5651	reduction	abstract[277]	new[277]	_	_
48-18	5652-5654	in	abstract[277]	new[277]	_	_
48-19	5655-5662	histone	abstract[277]|animal[278]	new[277]|new[278]	_	_
48-20	5663-5667	H2AX	abstract[277]|animal[278]	new[277]|new[278]	_	_
48-21	5668-5669	,	abstract[277]|animal[278]	new[277]|new[278]	_	_
48-22	5670-5675	which	abstract[277]|animal[278]	new[277]|new[278]	_	_
48-23	5676-5684	mediates	abstract[277]|animal[278]	new[277]|new[278]	_	_
48-24	5685-5698	repair-factor	abstract[277]|animal[278]|abstract|event[280]	new[277]|new[278]|new|new[280]	_	_
48-25	5699-5710	recruitment	abstract[277]|animal[278]|event[280]	new[277]|new[278]|new[280]	_	_
48-26	5711-5714	and	abstract[277]|animal[278]	new[277]|new[278]	_	_
48-27	5715-5717	is	abstract[277]|animal[278]	new[277]|new[278]	_	_
48-28	5718-5726	required	abstract[277]|animal[278]	new[277]|new[278]	_	_
48-29	5727-5730	for	_	_	_	_
48-30	5731-5737	genome	abstract|abstract[282]	new|new[282]	_	_
48-31	5738-5747	stability	abstract[282]	new[282]	_	_
48-32	5748-5749	.	_	_	_	_
